Skip to content
2000
Volume 9, Issue 1
  • ISSN: 1567-2018
  • E-ISSN: 1875-5704

Abstract

The use of immunotherapy in the treatment of non-Hodgkin lymphomas has improved response rates and survival in this population. With widespread rituximab use and longer-term follow-up of patients receiving rituximab, infectious complications are increasing. These complications are of great concern in the AIDS-related lymphoma population. We review the data on activity and infectious toxicity of rituximab to date and as it pertains to the treatment of AIDSrelated non-Hodgkin lymphoma and Multicentric Castleman's disease.

© Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdd/10.2174/156720112798376005
2012-01-01
2025-09-03

  • From This Site

    /content/journals/cdd/10.2174/156720112798376005
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/content/journals/cdd/10.2174/156720112798376005
Loading

  • Article Type:     Research Article
Keyword(s): AIDS; AIDS related Lymphoma; bortezomib; CHOP; CODOX-IVAC; dose adjusted EPOCH; HAART; hepatitis B; hepatitis C; HIV; JC Polyoma virus associated progressive multifocal leukoencyphalopathy; kaposi sarcoma; lymphoma; magrath regimen; Multicentric castleman's disease; non-hogdkin's lymphoma; rituximab

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test